WSD4000
Impaired sexual response and function in women
Pre-ClinicalEarly Feasibility Study planned for 2025 to refine clinical methodology and efficacy.
Key Facts
Indication
Impaired sexual response and function in women
Phase
Pre-Clinical
Status
Early Feasibility Study planned for 2025 to refine clinical methodology and efficacy.
Company
About Futura Medical
Futura Medical has transitioned from a pre-revenue R&D group to a commercial-stage company with its lead product, Eroxon®, now available in over 15 countries worldwide. The company's strategy focuses on addressing the large, underserved OTC sexual health market through innovative, topically delivered gel formulations, with a pipeline that includes Eroxon® Intense and a women's health product, WSD4000. By partnering with leading consumer healthcare giants for marketing and distribution, Futura aims to leverage their resources and expertise to drive sales, build brand awareness, and achieve sustained profitability.
View full company profile